open access

Vol 85, No 5 (2017)
REVIEWS
Published online: 2017-10-30
Submitted: 2017-07-11
Accepted: 2017-08-01
Get Citation

Eosinophilic COPD ― a distinct phenotype of the disease

Damian Tworek, Adam Antczak
DOI: 10.5603/ARM.a2017.0045
·
Pubmed: 29083023
·
Adv Respir Med 2017;85(5):271-276.

open access

Vol 85, No 5 (2017)
REVIEWS
Published online: 2017-10-30
Submitted: 2017-07-11
Accepted: 2017-08-01

Abstract

Chronic Obstructive Pulmonary Disease (COPD) has been traditionally associated with neutrophilic inflammation of the bronchi. Studies from the early 1990s demonstrated that eosinophils may also get into the lower airways of patients with COPD and their increased numbers can be noticed during exacerbations as well as stable disease. Eosinophilic phenotype of COPD is characterized by several unique features, i.e. a specific pattern of airway inflammation and distinct clinical course or susceptibility to corticosteroid treatment. In this paper, we present an up-to-date review of the literature on clinical characteristics of eosinophilic COPD, as well as the role of eosinophils as a biomarker-guided therapy in COPD.

Abstract

Chronic Obstructive Pulmonary Disease (COPD) has been traditionally associated with neutrophilic inflammation of the bronchi. Studies from the early 1990s demonstrated that eosinophils may also get into the lower airways of patients with COPD and their increased numbers can be noticed during exacerbations as well as stable disease. Eosinophilic phenotype of COPD is characterized by several unique features, i.e. a specific pattern of airway inflammation and distinct clinical course or susceptibility to corticosteroid treatment. In this paper, we present an up-to-date review of the literature on clinical characteristics of eosinophilic COPD, as well as the role of eosinophils as a biomarker-guided therapy in COPD.

Get Citation

Keywords

COPD, eosinophils, biomarkers

About this article
Title

Eosinophilic COPD ― a distinct phenotype of the disease

Journal

Advances in Respiratory Medicine

Issue

Vol 85, No 5 (2017)

Pages

271-276

Published online

2017-10-30

DOI

10.5603/ARM.a2017.0045

Pubmed

29083023

Bibliographic record

Adv Respir Med 2017;85(5):271-276.

Keywords

COPD
eosinophils
biomarkers

Authors

Damian Tworek
Adam Antczak

References (32)
  1. Buist AS, McBurnie MA, Vollmer WM, et al. BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007; 370(9589): 741–750.
  2. Nizankowska-Mogilnicka E, Mejza F, Buist AS, et al. Prevalence of COPD and tobacco smoking in Malopolska region--results from the BOLD study in Poland. Pol Arch Med Wewn. 2007; 117(9): 402–410.
  3. Huang G, Xu XC, Zhou JS, et al. Neutrophilic Inflammation in the Immune Responses of Chronic Obstructive Pulmonary Disease: Lessons from Animal Models. J Immunol Res. 2017; 2017: 7915975.
  4. Kolsum U, Ravi A, Hitchen P, et al. Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma. Respir Res. 2017; 18(1): 73.
  5. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1994; 150(6 Pt 1): 1646–1652.
  6. Rohde G, Gevaert P, Holtappels G, et al. Soluble interleukin-5 receptor alpha is increased in acute exacerbation of chronic obstructive pulmonary disease. Int Arch Allergy Immunol. 2004; 135(1): 54–61.
  7. Kolsum U, Donaldson GC, Singh R, et al. Blood and sputum eosinophils in COPD; relationship with bacterial load. Respir Res. 2017; 18(1): 88.
  8. Balzano G, Stefanelli F, Iorio C, et al. Eosinophilic inflammation in stable chronic obstructive pulmonary disease. Relationship with neutrophils and airway function. Am J Respir Crit Care Med. 1999; 160(5 Pt 1): 1486–1492.
  9. Kolsum U, Ravi A, Hitchen P, et al. ECLIPSE investigators. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014; 44(6): 1697–1700.
  10. Kolsum U, Damera G, Pham TH, et al. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J Allergy Clin Immunol. 2017; 140(4): 1181–1184.e7.
  11. Mitchell PD, O'Byrne PM. Biologics and the lung: TSLP and other epithelial cell-derived cytokines in asthma. Pharmacol Ther. 2017; 169: 104–112.
  12. Tworek D, Majewski S, Szewczyk K, et al. Serum IL-33 in Stable COPD with Sutum Eosinohilia. C74 Adv Transl COPD American Thoracic Society; 2017. p. : A6319–A6319.
  13. Soter S, Barta I, Antus B. Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide. Inflammation. 2013; 36(5): 1178–1185.
  14. Gao J, Zhang M, Zhou L, et al. Correlation between fractional exhaled nitric oxide and sputum eosinophilia in exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2017; 12: 1287–1293.
  15. Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016; 193(9): 965–974.
  16. Bafadhel M, Davies L, Calverley PMA, et al. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J. 2014; 44(3): 789–791.
  17. Couillard S, Larivée P, Courteau J, et al. Eosinophils in COPD Exacerbations Are Associated With Increased Readmissions. Chest. 2017; 151(2): 366–373.
  18. Bafadhel M, Greening NJ, Harvey-Dunstan TC, et al. Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. Chest. 2016; 150(2): 320–328.
  19. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60(11): 925–931.
  20. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007; 29(5): 906–913.
  21. Negewo NA, McDonald VM, Baines KJ, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis. 2016; 11: 1495–1504.
  22. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015; 3(6): 435–442.
  23. Siddiqui SH, Guasconi A, Vestbo J, et al. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015; 192(4): 523–525.
  24. Watz H, Tetzlaff K, Wouters EFM, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016; 4(5): 390–398.
  25. Wedzicha JA, Calverley PMA, Seemungal TA, et al. INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008; 177(1): 19–26.
  26. Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007; 176(2): 162–166.
  27. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014(3): CD010115.
  28. Wedzicha JA, Singh D, Vestbo J, et al. FORWARD Investigators. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014; 108(8): 1153–1162.
  29. Pavord ID, Lettis S, Anzueto A, et al. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med. 2016; 4(9): 731–741.
  30. Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014; 44(6): 1428–1446.
  31. Dasgupta A, Kjarsgaard M, Capaldi D, et al. A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis. Eur Respir J. 2017; 49(3).
  32. Pliskevich D. Efficacy and tolerability of EPs® 7630 in patients with chronic obstructive pulmonary disease (COPD). http://isrctn.org/>. .

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl